RSV is genuinely dangerous for adults 65 and older. It sends roughly 58 out of every 100,000 older adults to the hospital each season, and about 1 in 10 of those hospitalized die within 30 days. While most people think of RSV as a childhood illness, it poses a serious and often underrecognized threat to seniors, particularly those with existing heart or lung conditions.
How Severe RSV Gets in Older Adults
RSV hits older adults harder than most people expect. In a large English hospital study during the 2023-24 winter season, 30-day mortality among hospitalized seniors with RSV was 10.6%, which is comparable to influenza at 8.7%. A separate study found even starker numbers: patients hospitalized for RSV had a 58% higher risk of dying within 30 days compared to those hospitalized for flu, and were 48% more likely to need intensive care.
The reason RSV is so harmful in this age group comes down to aging immune systems and the burden of chronic disease. In the English hospital study, 81% of seniors hospitalized with RSV had at least one underlying health condition, and 26% had weakened immune systems. RSV doesn’t just cause a lung infection. It destabilizes the whole body, triggering flare-ups of conditions that were previously under control.
The Threat to Hearts and Lungs
One of the most important findings in recent years is how profoundly RSV affects the cardiovascular system, not just the respiratory system. A study of nearly 12,000 adults hospitalized with RSV in the United States found that heart and lung complications were common in the weeks following infection. The most frequent events were irregular heart rhythms, COPD flare-ups, heart failure episodes, heart attacks, and strokes.
The risk spikes sharply in the first week. For people with COPD, the risk of a flare-up was 23 times higher than baseline during the first seven days after RSV hospitalization. For heart failure, the risk was 12.5 times higher in that same window. These aren’t small bumps. They represent a dramatic and dangerous period of vulnerability.
What makes this particularly concerning is how long the elevated risk lasts. Heart failure risk remained significantly higher for up to 84 days after hospitalization. And looking out even further, 18.5% of RSV patients experienced a cardiovascular event within a year of discharge, a rate higher than patients hospitalized for flu, urinary tract infections, or bone fractures. Heart failure specifically was more common after RSV than after any of those other conditions, even in patients with no prior heart problems.
Who Faces the Highest Risk
Not every older adult faces the same level of danger. Several factors dramatically increase the odds of a severe outcome:
- Nursing home residents face hospitalization rates of about 367 per 100,000, more than six times the overall rate for seniors.
- Blood cancers carry the highest hospitalization rate of any single condition, at 399 per 100,000.
- COPD brings a rate of roughly 270 per 100,000.
- Functional dependence (needing help with daily activities) pushes the rate to about 348 per 100,000.
For healthy adults under 85 without these risk factors, the hospitalization rate drops below 40 per 100,000. That’s still not negligible, but it’s a fraction of the risk faced by someone in a nursing home or living with chronic lung disease. Age compounds the danger: adults over 74 with COPD or functional limitations, and those over 84 with asthma or cardiovascular disease, are considered the highest priority groups for preventive measures.
Why RSV Is Easy to Miss in Seniors
Part of what makes RSV dangerous in older adults is that it often looks like an ordinary cold at first. Early symptoms include a runny nose, sore throat, headache, and low-grade fever. In a healthy younger adult, that’s usually all it amounts to.
In seniors, two warning signs suggest RSV rather than a simple cold. The first is wheezing, a whistling sound during breathing that signals the virus has moved deeper into the airways. The second is a pattern of worsening rather than improving. Colds generally peak and then gradually resolve. RSV in an older adult can start mild and then escalate over several days, progressing to a worsening cough, difficulty breathing, or a bluish or grayish tint to the skin.
Diagnosis adds another challenge. Rapid antigen tests, the kind that give results in minutes, are not recommended for older adults because they miss too many cases. Seniors shed less virus than young children, which makes these quick tests unreliable. The preferred method is a molecular test (PCR), which is sensitive enough to detect the virus even when viral levels are low. If you’re an older adult with a respiratory illness that’s getting worse rather than better, asking specifically about RSV testing is reasonable, since many providers default to checking only for flu and COVID.
Recovery Takes Longer Than Expected
Even for seniors who avoid the ICU, recovery from RSV can be a prolonged process. The acute illness typically lasts one to two weeks, but the downstream effects on the heart and lungs can persist for months. The elevated risk of heart failure lasting nearly three months post-hospitalization means that the “recovery period” extends well beyond when the cough clears up.
For seniors who were already managing heart disease or lung conditions, an RSV hospitalization can mark a turning point. The exacerbation of chronic illness, including lung disease, heart disease, and frailty, was one of the most common reasons older adults were admitted to the hospital with RSV, accounting for a combined incidence of about 33 per 100,000. In practical terms, this means RSV can push someone from a stable chronic condition into a more advanced stage of illness, with lasting consequences for independence and quality of life.
Prevention Options for Older Adults
RSV vaccines for adults 60 and older became available in 2023. These vaccines are designed to reduce the risk of severe lower respiratory illness, which is the form of RSV that leads to hospitalization and the dangerous cascade of heart and lung complications described above. For people in the highest risk categories, particularly nursing home residents, those with COPD or heart failure, and those with blood cancers, the potential benefit is substantial given the hospitalization rates these groups face.
Beyond vaccination, reducing exposure matters. RSV spreads through respiratory droplets and contaminated surfaces, and it moves efficiently through congregate settings like nursing homes. Basic measures like hand hygiene and avoiding close contact with people who have cold symptoms offer some protection, though they’re imperfect. For older adults living in long-term care facilities, where hospitalization rates exceed 300 per 100,000, even modest reductions in transmission can prevent serious outcomes.